Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.56 |
| ▸ | HPGDS | O60760 | 1/20 | 0.38 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.37 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1118437 | 0.87 | GPR119 (0.66) | GPR119HPGDSEPHA2KDREPHB4 | |
| Hydrochloric Acid SCHEMBL1661798 | 0.86 | GPR119 (0.65) | GPR119HPGDSEPHA2KDREPHB4 | |
| SCHEMBL1118607 | 0.84 | GPR119 (0.71) | GPR119KCNJ1F2RL3 | |
| SCHEMBL1118544 | 0.84 | GPR119 (0.67) | GPR119KCNJ1 | |
| SCHEMBL1118470 | 0.84 | GPR119 (0.67) | GPR119KCNJ1 | |
| SCHEMBL1118409 | 0.82 | GPR119 (0.83) | GPR119KCNJ1 | |
| SCHEMBL13341924 | 0.82 | GPR119 (0.59) | GPR119KCNJ1EPHA2KDREPHB4 | |
| SCHEMBL1118421 | 0.82 | GPR119 (0.50) | GPR119HPGDSEPHA2KDREPHB4 | |
| SCHEMBL1118335 | 0.82 | GPR119 (0.64) | GPR119 | |
| SCHEMBL1118497 | 0.82 | GPR119 (0.62) | GPR119EPHA2KDREPHB4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10292983-B2 | Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions | CYMABAY THERAPEUTICS, INC. (US) | 2019-05-21 | — | — | US | disclosed |
| US-10292983-B2 | Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions | CYMABAY THERAPEUTICS, INC. (US) | 2019-05-21 | — | — | US | disclosed |
| US-9925189-B2 | Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders | CYMABAY THERAPEUTICS, INC. (US) | 2018-03-27 | — | — | US | disclosed |
| US-9925189-B2 | Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders | CYMABAY THERAPEUTICS, INC. (US) | 2018-03-27 | — | — | US | disclosed |
| US-9925189-B2 | Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders | CYMABAY THERAPEUTICS, INC. (US) | 2018-03-27 | — | — | US | disclosed |
| US-20180036307-A1 | OXYMETHYLENE ARYL COMPOUNDS FOR TREATING INFLAMMATORY GASTROINTESTINAL DISEASES OR GASTROINTESTINAL CONDITIONS | CYMABAY THERAPEUTICS INC (US) | 2018-02-08 | — | — | US | disclosed |
| US-20180036307-A1 | OXYMETHYLENE ARYL COMPOUNDS FOR TREATING INFLAMMATORY GASTROINTESTINAL DISEASES OR GASTROINTESTINAL CONDITIONS | CYMABAY THERAPEUTICS INC (US) | 2018-02-08 | — | — | US | disclosed |
| US-20180036307-A1 | OXYMETHYLENE ARYL COMPOUNDS FOR TREATING INFLAMMATORY GASTROINTESTINAL DISEASES OR GASTROINTESTINAL CONDITIONS | CYMABAY THERAPEUTICS INC (US) | 2018-02-08 | — | — | US | disclosed |
| WO-2018026890-A1 | OXYMETHYLENE ARYL COMPOUNDS FOR TREATING INFLAMMATORY GASTROINTESTINAL DISEASES OR GASTROINTESTINAL CONDITIONS | CYMABAY THERAPEUTICS (US) | 2018-02-08 | — | — | WO | disclosed |
| US-20180021335-A1 | HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | CYMABAY THERAPEUTICS INC (US) | 2018-01-25 | — | — | US | disclosed |
| US-20100087465-A1 | HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | METABOLEX, INC. | 2010-04-08 | — | — | US | disclosed |
| US-7638541-B2 | treatment of Type II diabetes and other diseases associated with poor glycemic control | METABOLEX INC. (US) | 2009-12-29 | — | — | US | disclosed |
| US-7638541-B2 | treatment of Type II diabetes and other diseases associated with poor glycemic control | METABOLEX INC. (US) | 2009-12-29 | — | — | US | disclosed |
| US-20090270404-A1 | OXYMETHYLENE ARYL COMPOUNDS AND USES THEREOF | METABOLEX, INC. | 2009-10-29 | — | — | US | disclosed |
| US-20090270404-A1 | OXYMETHYLENE ARYL COMPOUNDS AND USES THEREOF | METABOLEX, INC. | 2009-10-29 | — | — | US | disclosed |
| US-20090270404-A1 | OXYMETHYLENE ARYL COMPOUNDS AND USES THEREOF | METABOLEX, INC. | 2009-10-29 | — | — | US | disclosed |
| WO-2009123992-A1 | OXYMETHYLENE ARYL COMPOUNDS AND USES THEREOF | METABOLEX, INC. (US) | 2009-10-08 | — | — | WO | disclosed |
| US-20090054475-A1 | treatment of Type II diabetes and other diseases associated with poor glycemic control | METABOLEX, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| US-20090054475-A1 | treatment of Type II diabetes and other diseases associated with poor glycemic control | METABOLEX, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| WO-2008083238-A2 | HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | METABOLEX INC. (US) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087465-A1 | HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | GPR119, INSR, GLP1R | GPR119 1/4885HPGDS 1274/4885KCNJ1 1458/4885 |
| US-10292983-B2 | Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions | GPR119, GIPR, GLP1R | GPR119 1/4885HPGDS 640/4885KCNJ1 1639/4885 |
| US-20090270404-A1 | OXYMETHYLENE ARYL COMPOUNDS AND USES THEREOF | GPR119, GLP1R, DPP4 | GPR119 1/4885HPGDS 1275/4885KCNJ1 1826/4885 |
| US-20180036307-A1 | OXYMETHYLENE ARYL COMPOUNDS FOR TREATING INFLAMMATORY GASTROINTESTINAL DISEASES OR GASTROINTESTINAL CONDITIONS | GPR119, GIPR, GLP1R | GPR119 1/4885HPGDS 640/4885KCNJ1 1639/4885 |
| US-20180021335-A1 | HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | GPR119, INSR, GLP1R | GPR119 1/4885HPGDS 1274/4885KCNJ1 1458/4885 |
| US-20090054475-A1 | treatment of Type II diabetes and other diseases associated with poor glycemic control | SLC5A2, IAPP, GPR119 | GPR119 3/4885HPGDS 2064/4885KCNJ1 1108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.